Search Results
You are looking at 1 - 10 of 17 items for
- Author or Editor: Xuebin Wang x
- Refine by Access: All Content x
Abstract
In this study, the preparation of the 99m TcN complex of DMSA (dimercaptosuccinicacid) was carried out as a freeze-dried formulation, through a simple procedureinvolving the initial of 99m TcO 4 – with succinic dihydrazide in thepresence of stannous chloride as reducing agent, followed by the additionof the ligand DMSA to afford the final product. The radiochemical purity ofthe 99m TcN-DMSA complex was over 90% determined by thin layer chromatography.It was stable over 8 hours at room temperature. Its partition coefficientindicated that it was a good hydrophilic complex. Biodistribution in miceshowed that the 99m TcN-DMSA complex was accumulated in bone with high uptakeand good retention, suggesting it would be potentially useful as a bone imagingagent containing the [ 99m TcN] 2+ core. The biodistribution comparison inmice of the 99m TcN-DMSA complex and the 99m Tc-DMSA complex indicate thatthe presence of the 99m Tc nitrido group significantly alters the biologicalproperties of the 99m Tc complex.
Abstract
In order to seek a new class of brain perfusion imaging agent containing[ 99m TcN]2+ core, the bis(N-isopropyl dithiocarbamato)nitrido technetium-99m complex [ 99m TcN(IPDTC)2 ] (IPDTC:N-isopropyldithiocarbamato) has been synthesized through a simple and efficient method,which can be utilized for the preparation of a radiopharmaceutical througha lyophilized formulation. The radiochemical purity of the complex was over90% determined by thin layer chromatography. No decomposition of the complexwas observed at room temperature over a period of 12 hours. Its partitioncoefficient indicated that it was a good lipophilic complex. Biodistributionin mice demonstrated that the complex was significantly retained into thebrain. The brain uptake (ID%/g) was 3.90, 2.67 and 1.54 and the brain/bloodratios were 1.26, 1.06 and 0.85 at 5, 30 and 60-minute post-injection, respectively.The results showed that the complex may lead to a further development of theradiopharmaceutical as a brain perfusion tracer.
Abstract
The bis(N-cyclohexyl, N-isopropyl dithiocarbamato) nitrido technetium-99m complex [99mTcN(CHIPDTC)2] (CHIPDTC: N-cyclohexyl, N-isopropyl dithiocarbamato) has been synthesized through a ligand-exchange reaction. The two-step procedure involved the initial reaction of 99mTcO4 - with succinic dihydrazide (SDH) in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexant, followed by the addition of the sodium salt of N-cyclohexyl, N-isopropyl dithiocarbamate. The radiochemical purity (RCP) of the complex was 96±2% as measured by thin layer chromatography (TLC). No decomposition of the complex at room temperature (r. t.) was observed within a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed that the complex was neutral. Biodistribution in mice indicated that the complex accumulated in the heart with high uptake and good retention. The heart/blood, heart/lung ratio was 6.28 and 1.35, respectively, at 60-minute post-injection, suggesting that it would be a potential myocardial perfusion imaging agent.
Abstract
The 99mTc(CO)3(H2O)-DEDT complex was prepared by a two-step procedure involving the preparation of the precursor fac-[99mTc(CO)3(H2O)3]+, followed by the addition of sodium salt of diethyl dithiocarbamate (DEDT). The radiochemical purity (RCP) of the product was over 90% as measured by thin layer chromatography (TLC). No decomposition of the complex at room temperature was observed over a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice demonstrated that the complex can penetrate the intact blood-brain barrier (BBB) and the brain uptake (ID%/g) was 4.22 at 5-minute post-injection, suggesting the complex may lead to a further development of the radiopharma ceutical as a brain perfusion tracer.
Abstract
The preparation of the bis(N-propyl dithiocarbamato) nitrido technetium-99m complex 99mTcN(PDTC)2 (PDTC: N-propyl dithiocarbamato) was carried out as a freeze-dried formulation, through a simple procedure involving the initial of 99mTcO4- with succinic dihydrazide in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexant, followed by the addition of the ligand sodium salt of N-propyl dithiocarbamate to afford the final product. The radiochemical purity of the complex was over 90%, as measured by thin layer chromatography. No decomposition of the complex at room temperature was observed over a period of 12 hours. Its partition coefficient indicated that it was a good lipophilic complex. Biodistribution in mice showed that the complex accumulated in the brain with high uptake. The brain uptake (ID%/g) was 5.07 and the brain/blood ratio 1.34 at 5-minute post-injection. This suggested a potential usefulness of the complex as a brain perfusion imaging agent.
Abstract
The bis(N-butyl dithiocarbamato) nitrido 99mTc complex [99mTcN(BDTC)2] (BDTC: N-butyl dithiocarbamato) has been synthesized through a ligand-exchange reaction. The two-step procedure consisted of an initial reaction of 99mTcO4 − with succinic dihydrazide (SDH) in the presence of stannous chloride as reducing agent and propylenediamine tetraacetic acid (PDTA) as complexing agent, and subsequent addition of sodium salt of N-butyl dithiocarbamate. The radiochemical purity of the complex was over 90%, as measured by thin layer chromatography. No decomposition of the complex at room temperature was observed over a period of 6 hours. Its partition coefficient indicated that it was a lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the complex accumulated in the brain with high uptake. The brain/blood ratio was 1.58, 1.67 and 1.20 at 5, 30 and 60-minute post-injection, respectively, suggesting this compound would be a potential cerebral imaging agent.
Abstract
In the present study, a novel 99mTc nitrido dithiocarbamate complex containing ether group, the bis(2-ethoxyethyl dithiocarbamato) nitrido 99mTc complex 99mTcN(EOEDTC)2 has been synthesized by the reduction of 99mTcO4 − into [99mTcN]2+ with stannous chloride in the presence of succinic dihydrazide and propylenediamine tetraacetic acid, followed by the addition of the corresponding dithiocarbamate ligand. The radiochemical purity of the complex was over 90% as measured by thin layer chromatography (TLC). In vitro studies showed that the complex possessed good stability. Its partition coefficient indicated that it was lipophilic complex. The electrophoresis results showed the complex was neutral. Biodistribution in mice showed that the complex accumulated in the heart and brain with high initial uptake, suggesting the complex may lead to a further development of the radiopharmaceutical as a heart and brain perfusion tracer.
Abstract
A conjugate of 6-hydrazinopyridine-3-carboxylic acid (HYNIC) with the amino analogue of metronidazole (MN) was synthesized through a multiple-step reaction. HYNIC-MN could be labeled easily and efficiently with 99mTc using N-(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine (tricine) and ethylenediamine -N,N′-diacetic acid (EDDA) as coligands to form the 99mTc–HYNIC–MN complex in high yield (>95%). Its partition coefficient indicated that it was a good hydrophilic complex. The tumor cell experiment showed that the 99mTc–HYNIC–MN complex had a certain hypoxic selectivity. The biodistribution studies of 99mTc–HYNIC–MN in Kunming mice bearing S180 tumor showed a favorable tissue distribution profile with high tumor uptake, and low or negligible accumulation in non-target organs, suggesting 99mTc–HYNIC–MN would be a novel potential tumor hypoxia imaging agent.
Abstract
This study developed a modified pretinning method for labeling erythrocytes with technetium-99m in vitro using a kit which contains stannous chloride stabilized with gentisic acid (GA) in lyophilized form. This GA-kit is a sterile closed system that does not require centrifugation, washing and separation of the RBCs. The kit is simple to use and labeling takes 
30 min with a typical labeling efficiency of 97.3%±1.2% for 60 determinations. Imaging studies were performed in rabbit using GA-kit in vitro labeling procedure and PYP-kit in vivo labeling. It shows that the heart-to-background ratio with GA in vitro labeling were significantly higher than with in vivo labeling. Leukocytes labeling with technetium-99m using the same GA kit also was studied. The labeling efficiency was 20–41%. Thus, the GA kit is versatile and cost-effective.
Abstract
A conjugate of 6-hydrazinopyridine-3-carboxylic acid (HYNIC) with aminomethylenediphosphonic acid (AMDP) was synthesized through a multiple-step reaction. HYNIC–AMDP could be labeled easily and efficiently with 99mTc using N-(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine (tricine) as coligand to form the 99mTc–HYNIC–AMDP complex in high yield (> 95%). Its partition coefficient indicated that it was a good hydrophilic complex. The biodistribution studies of 99mTc–HYNIC–AMDP in normal ICR mice showed that this complex had high bone uptake and low or negligible accumulation in non-target organs. As compared with 99mTc–MDP, 99mTc–HYNIC–AMDP had a higher bone uptake and the ratios of bone/blood and bone/muscle at early time after injection, suggesting that it could be potentially useful for bone imaging at an earlier time after injection according to further investigations of the biological behavior of this complex.
